Related Experiment Video
Updated: May 10, 2025

05:14
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
970
Cardiovascular involvement in ANCA-associated vasculitis.
Ahmad Sarmad1, Zohreh Gholizadeh Ghozloujeh2, Paul E Hanna3
1Department of Medicine, Loma Linda University, Loma Linda, CA, USA.
Summary
Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have a significantly increased risk of cardiovascular events. This review explores AAV
Area of Science:
- Rheumatology
- Cardiology
- Immunology
Background:
- Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic necrotizing vasculitis with substantial cardiovascular implications.
- AAV patients exhibit a 65% elevated risk for cardiovascular events, including myocardial infarction and stroke.
Purpose of the Study:
- To review the current literature on cardiovascular involvement in AAV.
- To focus on pathophysiology, risk factors, predictive models, and management strategies for cardiovascular complications in AAV.
Main Methods:
- Literature review of existing studies on AAV and cardiovascular disease.
- Analysis of pathophysiology, clinical manifestations, risk factors, and treatment outcomes.
Main Results:
- Cardiovascular manifestations in AAV include myocardial infarction, stroke, myocarditis, and aortitis.
- Pathophysiology involves endothelial dysfunction, vascular inflammation, and direct cardiac infiltration, worsened by traditional and non-traditional risk factors.
- Management requires cardiovascular risk reduction alongside disease control to minimize cardiac impact.
Conclusions:
- Despite advances, persistent cardiovascular morbidity and mortality in AAV necessitate improved predictive tools and personalized strategies.
- Further research is needed for enhanced prevention and management of cardiovascular complications in AAV patients.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K

